FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET

On March 26, 2025, the FDA approved cabozantinib (Cabometyx, Exelixis, Inc.) for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors and well-differentiated extra-pancreatic neuroendocrine tumors.